ABSTRACT

Objective We examined the hypothesis that baseline retinal vascular geometry in patients with proliferative diabetic retinopathy (PDR) predicts disease activity 6 months after panretinal photocoagulation (PRP).

Methods and analysis We included 47 eyes from 40 patients with treatment-naïve PDR in a 6-month prospective study. Diagnosis of PDR and disease activity was evaluated by wide-field fluorescein angiography (Optomap, Optos, Dunfermline, Scotland, UK). At baseline and 6-month follow-up, the retinal vessel geometry was measured on optic disc centred images using semi-automated software Vessel Assessment and Measurement Platform for Images of the Retina (VAMPIRE, Dundee, Scotland).

Results At baseline, mean age and duration of diabetes was 51.6 and 21.4 years, and 62.5% were men. Seventeen eyes (36.2%) had progression of PDR during follow-up. At baseline, we found higher retinal arteriolar calibre (31.3±0.8 vs 28.8±0.8 pixels, p=0.02) and venous fractal dimension (Fv) (1.257±0.011 vs 1.222±0.011, p=0.02) in eyes with progression of PDR as compared with eyes without progression. In a multiple logistic regression model, both higher retinal arteriolar calibre (OR 1.34, 95% CI, 1.09 to 1.64, p<0.01) and venular Fv (OR 1.15, 95% CI, 1.04 to 1.27, p<0.01) predicted progression of PDR. Venular calibre was seen to increase from baseline to month six regardless of disease progression (non-progression 45.0±0.7 vs 52.7±1.8 pixels, p<0.01; progression 46.2±0.8 vs 51.0±1.7 pixels, p<0.01).

Conclusion Our prospective study showed that arteriolar calibre and venular Fv at baseline were predictive of disease activity 6 months after PRP treatment in patients with treatment-naïve PDR.

INTRODUCTION

Diabetic retinopathy (DR) is a common microvascular complication of diabetes mellitus (DM). DR is a major cause of visual impairment related primarily to either diabetic macular oedema or to vitreous haemorrhage/tractional retinal detachment from proliferative DR (PDR). These complications are seen more frequently in individuals with poorly controlled diabetes, hypertension and/or long DM duration. Long-term epidemiological studies have reported up to 75% will have DR 10 years after diagnosis, particularly in persons with type 1 DM.

In the 1970s, the Diabetic Retinopathy Study reported that panretinal photocoagulation (PRP) reduced visual loss by more than 50% in patients with severe PDR. PRP is now the standard of care for eyes with PDR. However, currently all patients are given the same amount of PRP laser treatment. Some patients may, therefore, receive insufficient treatment, while excessive treatment may be
given to others. Patients who receive inadequate PRP might have progression of disease with tractional retinal detachment or vitreous haemorrhage, while others who have excessive PRP may develop side effects like visual field loss, night-blindness or diabetic macular oedema.10–13 The inability to predict progression of PDR despite PRP remains an important gap in the clinical management of PDR. Furthermore, standard PRP treatment has been challenged by the newer anti-vascular endothelial growth factor (VEGF) therapy. The DRCR.net protocol S demonstrated non-inferiority regarding progression of PDR and Early Treatment Diabetic Retinopathy Study (ETDRS) letters gained at 2-year follow-up.17

Advances in retinal imaging technology provide new opportunities to assess the retinal vascular geometry using semiautomated computer software. The literature predominantly reports on two different softwares used for accessing the retinal vascular geometry, namely the Vascular Assessment and Measurement Platform for Images of the Retina software (VAMPIRE, Dundee, Scotland) and the Singapore I Vessel Assessment Software (SIVA, National University of Singapore, Singapore). Such algorithms allow for a non-invasive quantitative way to assess the retinal vascular tree. A number of studies have found retinal vascular geometry to be closely related to the presence and severity of DR. Studies have reported on increased DR severity to be linked to narrowing of the arteriolar and widening of the venular vessel calibres,14–17 increased retinal fractals18 and changes in tortuosity.19

The aim of our study was to predict the outcome of PRP treatment in eyes with PDR using non-invasive structural retinal vascular measurements of fundus photographs. We hypothesise that retinal vessel geometry at baseline could be used to identify patients at risk of progression of PDR after PRP treatment.

MATERIALS AND METHODS
We conducted a prospective clinical interventional study of 47 eyes from 40 patients with treatment-naïve PDR, who were followed for 6 months at Odense University Hospital, Odense, Denmark. The exclusion criteria were age under 18 years, pregnancy, clinical significant macular oedema or treatment-demanding cataract in the study eye.

At baseline, all patients provided a full medical history and underwent thorough mydriatic slit lamp examination (tropicamid 10 mg/mL and phenylephrine 10%). Optical coherence tomography (OCT) and fundus photography with 45° optic disc (OD) centred image, were captured by a 3D OCT-2000 Spectral domain OCT (Topcon, Tokyo, Japan), and wide-field fundus images and fluorescein angiography (Optomap; Optos, Dunfermline, Scotland, UK) were performed. The baseline examinations were completed by measurement of blood pressure (Omron 705CP, Hoofddorp, The Netherlands) and haemoglobin A1c (HbA1c). All examinations were carried out by trained personnel.

After baseline examinations, all patients received PRP in two sessions 1 week apart using a navigated laser-system (NAVILAS, OD-OS GmbH, Berlin, Germany). First laser session was focused in the inferior half of the retina, and the second laser session in the superior half of the retina. Local anaesthetic (oxybuprocain hydrochloride 0.4%) was administered prior to PRP, and a NAVILAS 34 mm or 38 mm contact lens was used during the treatment session. All treatments were given by certified personnel (TLT and JG). All baseline examinations were repeated after 6 months. Progression of PDR was defined as new vessel formation, expanding area of minimum one proliferation or increased area of fluorescein leakage on angiography, as defined by clinical guidelines.

Rescue PRP was given for eyes with progression of PDR at follow-up month three, and progression of PDR was defined as progression at any point during follow-up.

Image assessment
Fundus images were captured as 45° OD centred images (3D OCT-2000 Spectral domain OCT) acquired at baseline, and month six were used for retinal vessel geometry analyses using the verified semiautomated VAMPIRE software. All images were graded by a single trained grader (TLT) in accordance with the VAMPIRE grading protocol. Details and validation have been reported elsewhere.20–25 In brief, the software automatically detects the OD and foveal area. If necessary, manual adjustment of the OD and foveal tracing are possible. The software places a three-zoned grid around the OD, located 0.0–2.0 disc diameters from the margin of the OD (figure 1). The
three zones are labelled A–C (zone A 0.0–0.5 disc diameter from the OD, zone B 0.5–1.0 disc diameter from the OD and zone C 1.0–2.0 disc diameter from the OD), and the vessels are automatically traced by the software and labelled as arterioles (red) or venules (blue). Corrections of vessel-labelling and artefacts are done by the grader. We measured the following: central retinal artery and vein calibre (CRAE, CRVE) in zone B using a revised ‘Big-6-formula’, and the vessel tortuosity and fractal dimension (F_d) in zone C.

Twenty images were masked and graded twice at two different timepoints by the same grader (TLT). The intra-grader intraclass correlation (ICC) was calculated using CRAE and CRVE. The ICC was found to be of strong agreement (ICC 0.97).

Statistical analyses
All statistical calculations were performed using STATA V.14.2 (StataCorp), and p values under 0.05 were considered statistically significant. If both eyes in one patient presented with PDR, we included both eyes in the study. In order to manage potential intra-group correlation between two eyes from the same patient, we used cluster commands. Cluster commands allow for observations to be independent across groups (clusters) but not necessarily within groups. At baseline, categorical data are presented as percentage and continuous data concerning demographic data as mean with SD. Vessel geometric variables are presented as mean with SD. Differences between patients with progression and non-progression of PDR at baseline and month six were compared by linear regression. Multiple logistic regression was performed with retinal vessel geometry (calibre, tortuosity, F_d) as predictors for progression of PDR (with adjustments for sex, age, duration of diabetes, HbA1c and total amount of laser spots). The ICC was calculated using the two-way mixed-effects model.

RESULTS
We examined 47 eyes from 40 patients. At baseline, mean±SD age and duration of diabetes were 51.6±13.9 and 21.4±11.6 years, and 62.5% were men. Mean±SD HbA1c and blood pressure were 70.9±18.1 mmol/mol and 154/85±22/14 mm Hg. At baseline, we found no difference between eye of the two subsequently formed groups (progression vs non-progression of PDR) in sex, age, duration of diabetes, HbA1c, blood pressure, smoking or total amount of laser spots delivered (table 1).

At baseline, we found a statistically significant higher arteriolar calibre and venous F_d in eyes with progression of PDR as compared with eyes with non-progression of PDR (calibre: 31.3±0.8 vs 28.8±0.8 pixels, p=0.02; F_d: 1.257±0.011 vs 1.222±0.011, p=0.02). In a multiple logistic regression model, a higher baseline retinal arteriolar calibre (OR 1.34 per one point increment, 95% CI 1.09 to 1.64, p<0.01) and venular F_d (OR 1.15 per 0.01 point increment, 95% CI 1.04 to 1.27, p<0.01) was independently associated with progression of PDR at follow-up month six.

We found a statistically significant increment in arteriolar and venular calibre in patients with non-progression of PDR from baseline to follow-up month six (arteriolar 28.8±0.8 vs 33.8±1.0 pixels, p=0.01; venular 45.0±0.7 vs 52.7±1.8 pixels, p<0.01), although this was not seen when performing multiple logistic regression. Furthermore, an increment in retinal venular calibre and arteriolar tortuosity were seen from baseline to follow-up month six in patients with progression of PDR, likewise this was not seen when performing multiple logistic regression (table 2).

DISCUSSION
In this prospective study of patients with treatment-naive PDR, we found the baseline arteriolar calibre and venous F_d to be predictive of disease activity 6 months after PRP.

| Demographics (40 patients/47 eyes) | Non-progression | Progression | P value |
|-----------------------------------|-----------------|-------------|---------|
| Patients/eyes, n                  | 27/30           | 13/17       | 0.13    |
| Male/female, n                    | 19/8            | 6/7         | 0.25    |
| Age, years                        | 53.3±13.9       | 48.0±14.0   | 0.63    |
| Duration of diabetes, years       | 21.8±11.7       | 20.5±11.6   | 0.63    |
| HbA1c, mmol/mol                    | 71.9±18.8       | 68.7±17.3   | 0.31    |
| Systolic blood pressure, mm Hg     | 157±24          | 147±18      | 0.72    |
| Diastolic blood pressure, mm Hg    | 86±14           | 83±14       | 0.94    |
| Smoker/non-smoker, n              | 8/19            | 4/9         | 0.73    |
| Laser spots, n                    | 1551.0±220.5    | 1552.0±234.3| 0.89    |
| Diabetes type 1/type 2, n         | 13/14           | 7/6         | 0.73    |

All values are represented as mean±SD. HbA1c, Glycated hemoglobin HbA1c, haemoglobin A1c.
Every 1.0 pixel point in wider arteriolar calibre at baseline was associated with a 34% increased risk of progression of PDR, and every 0.01 point higher FD was associated with a 15% increased risk of PDR progression, independent of other risk factors.

In patients with progression of PDR, we found the baseline arteriolar calibre to be wider compared with patients without progression at follow-up month six. Studies have postulated wider arteriolar calibre as a risk factor in the early development of DR. In a study by Broe et al, it was shown that reduced arteriolar calibres were associated with a 31% cumulative incidence of PDR after 16 years. However, the overall association between arteriolar calibre and DR is more complex, and studies conducted on large cohorts have reported on no associations, or even arteriolar calibre dilatation.

The literature is seen to be very inconclusive regarding retinal arteriolar calibre, in different stages of DR. To our knowledge, no other studies have looked at differences in retinal vascular parameters between patients with and without progression after PDR-treatment. At the level of PDR, the retinal arteriolar calibre should be expected to be affected by different systemic and microvascular factors. Traditionally systemic risk factors like duration of diabetes, glycaemic and blood pressure control are believed to have an impact on retinal vessel calibre. Our study might indicate that the microvascular capacity is radically changed, when an eye reaches the level of PDR. The hypoxic load increases and neovascularisations are formed. Thus, dilating the arterioles in order to increase the blood flow to the new vessels in eyes with reduced or damaged vascular capacity.

The FD explains the complexity of the retinal vascular tree; thus, a higher value equals a higher retinal vascular complexity. In our study, we found a higher FD in patients with progression of PDR as compared with patients with non-progression at follow-up month six. This could be due to a higher hypoxic load in patients with progression of PDR 6 months after PRP, thus resulting in a more complex vascular structure. The arteriolar and venular FD did not differ between the two groups from baseline to follow-up month six. Earlier studies have reported on a lower FD to be associated with a higher risk of developing PDR. In an earlier prospective study,

| Retinal vessel geometry | BL | 6M | P value |
|-------------------------|----|----|---------|
| Calibre (pixel)         |    |    |         |
| Arterial                |    |    |         |
| Non-progression         | 31 | 28.8 | 0.8 | 33.8 | 1.0 | <0.01* |
| Progression             | 18 | 31.3 | 0.8 | 34.0 | 0.8 | 0.03* |
| P value                 |    | 0.02* |         | 0.88 | |
| Venous                  |    |    |         |
| Non-progression         | 31 | 45.0 | 0.7 | 52.7 | 1.8 | <0.01* |
| Progression             | 18 | 46.2 | 0.8 | 51.0 | 1.7 | <0.01* |
| P value                 |    | 0.26 |         | 0.54 | |
| Tortuosity              |    |    |         |
| Arterial                |    |    |         |
| Non-progression         | 31 | −8.14 | 0.28 | −8.18 | 0.30 | 0.37 |
| Progression             | 18 | −7.69 | 0.49 | −8.35 | 0.11 | 0.03* |
| P value                 |    | 0.42 |         | 0.59 | |
| Venous                  |    |    |         |
| Non-progression         | 31 | −7.85 | 0.40 | −8.39 | 0.07 | 0.81 |
| Progression             | 18 | −8.32 | 0.06 | −8.34 | 0.09 | 0.68 |
| P value                 |    | 0.24 |         | 0.59 | |
| Fractal dimension       |    |    |         |
| Arterial                |    |    |         |
| Non-progression         | 31 | 1.210 | 0.013 | 1.201 | 0.014 | 0.51 |
| Progression             | 18 | 1.225 | 0.013 | 1.239 | 0.014 | 0.16 |
| P value                 |    | 0.38 |         | 0.05 | |
| Venous                  |    |    |         |
| Non-progression         | 31 | 1.222 | 0.011 | 1.240 | 0.008 | 0.07 |
| Progression             | 18 | 1.257 | 0.011 | 1.252 | 0.014 | 0.55 |
| P value                 |    | 0.02* |         | 0.43 | |

All values are represented as mean±SD. Differences between patients with non-progression and progression of proliferative diabetic retinopathy are given vertically, and changes from baseline (BL) to follow-up 6 months (6M) (paired data) are represented horizontally. *Statistically significant.
performed at our unit, we found no difference in $F_D$ at baseline between patients with progression and non-progression at follow-up month six.\cite{5} This difference could be due to the usage of two different computer softwares, the SIVA and VAMPIRE softwares. There are some evident differences between the two softwares. First of all, there is a difference in the postprocessing of retinal images. Furthermore, different mathematical algorithms are used to access the retinal vessel geometry.

Second, the SIVA software allows fare more grader-correction that the VAMPIRE software. The SIVA software allows for tracing of untraced vessels, correction of vessel crossings and deletion of vessel segments. The VAMPIRE software does not allow the abovementioned corrections. McGrory et al.\cite{33} reported on the agreement in measurements between the two softwares and concluded that caution should be taken when making inferences regarding the associations between retinal measures.

First of all, the arteriolar tortuosity was seen to increase from baseline to follow-up month six in patients with progression of PDR. Likewise, on this matter the literature is inconclusive. One prospective study reported on increased arteriolar tortuosity in patients with progression of PDR 6 months after PRP treatment, while another cross-sectional study found no association between PDR and retinal vascular tortuosity.\cite{32} One could speculate, if increased tortuosity could be associated with increased retinal ischaemia. Thereby the tortuosity would increase in patients with an increased or high ischaemic load and progression of PDR in this group is seen despite PRP treatment.

In our study, the arteriolar calibre was documented to increase from baseline to follow-up month six in the two groups regardless of PRP treatment. As stated earlier, it has been reported that the arteriolar vessel calibre decreases with increased severity of DR.\cite{17,20} Thus, narrow arteriolar vessels could be expected at the level of PDR. After PRP treatment, the ischaemic drive is thought to be reduced, and thereby a dilatation of the retinal vessels could be seen. In our study, the dilatation of the retinal vessels regardless of progression of PDR at follow-up month six could be due to the laser treatment itself. In a study by Klein et al.,\cite{20} the arteriolar calibre was found to be significantly smaller in eyes with PDR treated with PRP as compared with untreated eyes, although the time from PRP treatment to calibre measurement was unclear.

The venular calibre increased from baseline to month six regardless of disease progression. The literature is somewhat sparse on this topic. Prospective studies have reported on wider retinal venular calibre and increased incidence of PDR.\cite{14,34} However, a prospective study performed at our department on patients with PDR found no statistical change in retinal venular calibre at 6-month follow-up after PRP treatment regardless of disease progression.\cite{33} A change in the retinal venular calibre was not expected. Our findings showed an increase in the venular calibre that could be explained by a reduced autoregulatory function due to the long duration of DM, and the overall state of the vessels at the point of PDR.

The strengths of this study were the prospective design, and the use of a semiautomated validated computer software which minimised grader influence on the results. Limitations include the lack of refractive data on the cohort, and the relatively small sample size; larger cohorts are needed to investigate the disease process and its vascular characteristics further.

In conclusion, our prospective study showed that the arteriolar calibre and venular $F_D$ at baseline, using the VAMPIRE software, predict disease activity 6 months after PRP treatment in patients with treatment-naive PDR. We found increased retinal arteriolar and venular calibre from baseline to follow-up month six regardless of PRP treatment. Hence, structural retinal arteriolar and venular differences/changes could serve as individual markers of adequacy of PRP treatment in patients with PDR.
REFERENCES

1. Bressler SB, Beaulieu WT, Glassman AR, et al. Photocoagulation versus ranibizumab for proliferative diabetic retinopathy: should baseline characteristics affect choice of treatment? Retina 2019;39:1646-1654.

2. Grauslund J, Green A, Spjøte AK. Prevalence and 25 year incidence of proliferative retinopathy among Danish type 1 diabetic patients. Diabetologia 2009;52:1829–35.

3. Klein R, Lee KE, Knudtson MD, et al. Changes in visual impairment prevalence by period of diagnosis of diabetes: the Wisconsin epidemiologic study of diabetic retinopathy. Ophthalmology 2009;116:1937–42.

4. Antonetti DA, Klein R, Gardner TW. Diabetic retinopathy. N Engl J Med 2012;366:1227–39.

5. Klein R, Klein BE, Moss SE, et al. The Wisconsin epidemiologic study of diabetic retinopathy. XVI. The long-term incidence of macular edema. Ophthalmology 1995;102:7–16.

6. Klein R, Klein BE, Moss SE, et al. The Wisconsin epidemiologic study of diabetic retinopathy. II. prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1984;102:520–6.

7. Klein R, Klein BE, Moss SE, et al. The Wisconsin epidemiologic study of diabetic retinopathy. III. prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 1984;102:527–32.

8. Preliminary report on effects of photocoagulation therapy. The diabetic retinopathy study Research Group. Am J Ophthalmol 1976;81:383–96.

9. Gross JJ, Glassman AR, et al, Writing Committee for the Diabetic Retinopathy Clinical Research Network. Panretinal photocoagulation vs Intravitreous ranibizumab for proliferative diabetic retinopathy vs Intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. JAMA 2015;314:2137–46.

10. Photocoagulation treatment of proliferative diabetic retinopathy. clinical application of diabetic retinopathy study (DRS) findings, DRS report number 8, the diabetic retinopathy study Research Group. Ophthalmology 1984;91:583–600.

11. Ferris FL, Podgor MJ, Davis MD. Macular edema in diabetic retinopathy study patients. diabetic retinopathy study report number 12. Ophthalmology 1987;94:754–60.

12. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. early treatment diabetic retinopathy study Research Group. Ophthalmology 1991;98:766–85.

13. Pahor D. Visual field loss after argon laser panretinal photocoagulation in diabetic retinopathy: full- versus mild-scatter coagulation. Int Ophthalmol 1998;22:313–9.

14. Klein R, Klein BEK, Moss SE, et al. The relation of retinal vessel caliber to the incidence and progression of diabetic retinopathy: XIX: the Wisconsin epidemiologic study of diabetic retinopathy. Arch Ophthalmol 2004;122:76–83.

15. Rogers SL, Tikellis G, Cheung N, et al. Retinal arteriolar caliber predicts incident retinopathy: the Australian diabetes, obesity and lifestyle (AusDiab) study. Diabetes Care 2008;31:761–3.

16. Klein R, Klein BEK, Moss SE, et al. Retinal vessel caliber and microvascular and macrovascular disease in type 2 diabetes: XXI: the Wisconsin epidemiologic study of diabetic retinopathy. Ophthalmology 2007;114:1884–92.

17. Grauslund J, Hodgson L, Kawasaki R, et al. Retinal vessel calibre and micro- and macrovascular complications in type 1 diabetes. Diabetologia 2009;52:2213–7.

18. Grauslund J, Green A, Kawasaki R, et al. Retinal vascular fractals and microvascular complications in type 1 diabetes. Ophthalmology 2010;117:1400–5.

19. Sasonko MB, Wong TY, Nguyen TT, et al. Retinal vascular tortuosity in persons with diabetes and diabetic retinopathy. Diabetologia 2011;54:2409–16.

20. Perez-Rovira A, MacGillivray T, Trucco E, et al. Vampire: vessel assessment and measurement platform for images of the retina. Annu Int Conf IEEE Eng Med Biol Soc 2011;2011:3391–4.

21. Patton N, Aslam TM, MacGillivray T, et al. Retinal image analysis: concepts, applications and potential. Prog Retin Eye Res 2008;27:89–127.

22. Lisowska A, Annunziata R, Loh GK, et al. An experimental assessment of five indices of retinal vessel tortuosity with the RET-TORT public dataset. Annu Int Conf IEEE Eng Med Biol Soc 2014;2014:5414–7.

23. MacGillivray TJ, Paton N, Doublain FL, et al. Fractal analysis of the retinal vascular network in fundus images. Annu Int Conf IEEE Eng Med Biol Soc 2007;2007:6456–9.

24. Knudtson MD, Lee KE, Hubbard LD, et al. Revised formulas for summarizing retinal vessel diameters. Curr Eye Res 2003;27:143–9.

25. Cheung N, Rogers SL, Donaghue KC, et al. Retinal arteriolar dilation predicts retinopathy in adolescents with type 1 diabetes. Diabetes Care 2008;31:1842–6.

26. Klein R, Klein BEK, Moss SE, et al. Retinal vascular caliber in patients with type 2 diabetes: the Wisconsin epidemiologic study of diabetic retinopathy: XX. Ophthalmology 2006;113:4488–89.

27. Broe R, Rasmussen ML, Frydka-Jaersen O, et al. Retinal vascular fractals predict long-term microvascular complications in type 1 diabetes mellitus: the Danish cohort of pediatric diabetes 1987 (DCPD1987). Diabetologia 2014;57:2215–21.

28. Crosby-Nwaobi R, Heng LZ, Sivaprasad S. Retinal vascular calibre, geometry and progression of diabetic retinopathy in type 2 diabetes mellitus. Ophthalmologica 2012;228:84–92.

29. Islam FMA, Nguyen TT, Wang JJ, et al. Quantitative retinal vascular calibre changes in diabetes and retinopathy: the Singapore Malay diabetes. Br J Ophthalmol 2011;100:1359–65.

30. Yang X, Deng Y, Gu H, et al. Relationship of retinal vascular calibre and diabetic retinopathy in Chinese patients with type 2 diabetes mellitus: the Desheng diabetic eye study. Br J Ophthalmol 2016;100:1359–65.

31. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet 2010;376:124–36.

32. Torp TL, Kawasaki R, Wong TY, et al. Temporal changes in retinal vascular parameters associated with successful panretinal photocoagulation in proliferative diabetic retinopathy: a prospective clinical interventional study. Acta Ophthalmol 2018;96:405–10.

33. McGoray S, Taylor AM, Pellegrini E, et al. Towards standardization of quantitative retinal vascular parameters: comparison of SIVA and vampire measurements in the Lothian birth cohort 1936. Trans Vis Sci Technol 2018;7:12.

34. Roy MS, Klein R, Janal MN. Retinal venular diameter as an early indicator of progression to proliferative diabetic retinopathy with and without high-risk characteristics in African Americans with type 1 diabetes mellitus. Arch Ophthalmol 2011;129:6–15.